Abstracts tagged "cytokines"

Abstract Number: 1157 • ACR Convergence 2022
Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
Brenda Seymour¹, Brandon Trent², Brendan Allen³, Adam Berlinberg¹ and Kristi Kuhn³, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado Anschutz Medical Campus, Eugene, OR, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: While intestinal dysbiosis and the Th17 pathway are linked to the pathophysiology of spondyloarthritis (SpA), the mechanisms by which this occurs are unknown. We…
Abstract Number: 1940 • ACR Convergence 2022
Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers
Marci Macaraeg, Michael Matt, Grant Schulert, Elizabeth Baker and Elizabeth Handorf, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Unexplained, recurrent fevers are a common presentation to pediatric rheumatology and a cause of significant burden to affected families due to days of daycare…
Abstract Number: 0615 • ACR Convergence 2022
Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis
Qi Cheng, Mo chen, Mengdan Liu, Xin chen, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…
Abstract Number: 1440 • ACR Convergence 2022
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
Fatima Alduraibi¹, Kathryn Sullivan¹, Winn Walter Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…
Abstract Number: 1951 • ACR Convergence 2022
Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
Claudia De Luis zarate¹, Cristina Almeida Santiago², Maria Vanesa Hernández Hernández³, antonia De Vera González⁴, Alejandra González Delgado⁴, Juan Carlos Quevedo Abeledo⁵ and Ivan Ferraz Amaro⁶, ¹Hospital Universitario de Canarias, Puerto de la Cruz, Spain, ²Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³HUC, San Cristóbal de la, Spain, ⁴HOSPITAL UNIVERSITARIO DE CANARIAS, Santa Cruz de Tenerife, Spain, ⁵Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, ⁶Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain
Background/Purpose: Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis…
Abstract Number: 0621 • ACR Convergence 2022
Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm
Siska Wilantri¹, Cindy Strehl¹, Dimas Abdirama¹, Timo Gaber¹, Robert Biesen² and Frank Buttgereit¹, ¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Background/Purpose: Clinical symptoms of rheumatoid arthritis (RA), including pain, joint stiffness, and swelling, exhibit a distinct circadian rhythm that exacerbates in the early morning in…
Abstract Number: 1447 • ACR Convergence 2022
Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers
Carolina Munoz¹, Michelle Barraclough², Juan Pablo Diaz-Martinez¹, Jiandong Su¹, Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, May Choi⁶, Dennisse Bonilla¹, Simone Appenzeller⁷, Patricia Katz⁸, Dorcas Beaton⁹, Robin Green⁵, Joan Wither¹⁰ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸UCSF, San Rafael, CA, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus…
Abstract Number: 2214 • ACR Convergence 2022
Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)
Christopher Redmond¹, Moses Kitakule², Riccardo Castagnoli³, Francesco Licciardi⁴, Cihan Oguz⁵, Maria Cecilia Poli⁶, Aran Son⁵, Sarah Weber⁵, Luigi Notarangelo⁷, Helen Su⁸ and Daniella Schwartz⁹, ¹National Institutes of Health, Rockville, MD, ²Columbia University, New York, NY, ³National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁴OSPEDALE REGINA MARGHERITA, Torino, Italy, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶Roberto del Rio, Santiago, Chile, ⁷NIAID/NIH, Bethesda, MD, ⁸NIH/NIAID, Bethesda, MD, ⁹National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable…
Abstract Number: 0623 • ACR Convergence 2022
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
Edoardo Prediletto¹, Cankut Cubuk², Elena Pontarini³, Felice Rivellese², Alessandra Nerviani², Davide Lucchesi³, Mattia Caliste¹, Elisa Corsiero¹, Manzoor Ahmed³, rebecca hands³, Myles Lewis², Costantino Pitzalis² and Michele Bombardieri⁴, ¹Wlliam Harvey Research Institute Queen Mary University on London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³William Harvey Research Institute, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom
Background/Purpose: Despite advances in the treatment of Rheumatoid Arthritis (RA), synthetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness…
Abstract Number: 1554 • ACR Convergence 2022
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
Cameron Rankin¹, Peter Grayson², Bates Gribbons³, Kaitlin Quinn⁴, Christopher Redmond⁵ and Wanxia Tsai¹, ¹NIAMS/NIH, Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³McGovern Medical School, Colleyville, TX, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁵National Institutes of Health, Rockville, MD
Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…
Abstract Number: 2240 • ACR Convergence 2022
Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice
Yuki Ichimura¹, Risa Konishi¹, Toshifumi Nomura², Manabu Fujimoto³ and Naoko Okiyama¹, ¹Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, ²University of Tsukuba, Tsukuba, Ibaraki, Japan, ³Osaka University, Suita, Japan
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody-associated DM sometimes…
Abstract Number: 0626 • ACR Convergence 2022
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Meena Afroze Shanta¹, Farheen Sultan Shaikh², Bhanupriya Madarampalli³ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…
Abstract Number: 1559 • ACR Convergence 2022
Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
Yusuke Ushio¹, Risa Wakiya², Kiyo Ueeda³, Tomohiro Kameda², shusaku nakashima⁴, Hiromi Shimada², Mikiya Kato², taichi miyagi⁵, Rina Mino⁶, Kanako Chujo⁷ and Hiroaki Dobashi⁸, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Kagawa University, Kagawa, Japan, ³Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁵Kagawa University, Kidagun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan
Background/Purpose: Apremilast, the small-molecule phosphodiesterase -4 inhibitor, was approved for the treatment of recurrent oral ulcers associated with Behcet's disease (BD) in Japan from September…
Abstract Number: 2264 • ACR Convergence 2022
Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Andrea Largent¹, Jane Buckner², David Rawlings¹ and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression…
Abstract Number: 0636 • ACR Convergence 2022
Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions
Background/Purpose: There is a pressing need to identify novel therapeutic approaches and noninvasive biomarkers in lupus nephritis (LN). In this study, we quantified serum soluble…

« Previous Page
1
…
8
9
10
11
12
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].